[beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].

Abstract

A 55-year-old man was admitted to our hospital because of leukocytosis and microcytic anemia with hypochromia, target cells, and increased levels of hemoglobin A2 and hemoglobin F. The results of a gene analysis yielded a diagnosis of chronic myelogenous leukemia and beta-thalassemia minor. A gradual increase in hemoglobin was observed during hydroxyurea therapy, which was performed over a 12-week period. This increment appeared to be due to suppressed production of myeloid cells. It was been reported that hydroxyurea increases total hemoglobin due to increased hemoglobin F synthesis in patients with beta-thalassemia. However, hydroxyurea had no clear influence on hemoglobin concentration in this case.

• Authors: K Chiba, M Kurosawa, T Kondo, S Suzuki, M Musashi, M Asaka, M Imamura, Y Hattori, Y Oba
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 41 Issue 1 Pg. 61-4 (Jan 2000) ISSN: 0485-1439 [Print] Japan
• PMID: 10695401 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Hemoglobins
• Globins
• Hydroxyurea

Topics

• Antineoplastic Agents (administration & dosage)
• Globins (genetics)
• Hemoglobins (metabolism)
• Humans
• Hydroxyurea (administration & dosage)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (complications, drug therapy)
• Male
• Middle Aged
• Mutation
• beta-Thalassemia (blood, complications, diagnosis)